» Articles » PMID: 18054751

Clinical Course in Crohn's Disease: Results of a Norwegian Population-based Ten-year Follow-up Study

Overview
Specialty Gastroenterology
Date 2007 Dec 7
PMID 18054751
Citations 225
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Most studies concerning the clinical course in CD are retrospective or based on selected patient groups. Our aim was to assess the course of CD in a prospective population-based follow-up study and to identify possible prognostic risk factors for complications on the basis of information obtained at initial diagnosis.

Methods: From 1990-1994, a population-based cohort of 843 new cases of inflammatory bowel disease was recruited in South-Eastern Norway. The cohort was systematically followed up at 1, 5, and 10 years after diagnosis.

Results: Of 237 patients classified as CD, 197 completed the 10 years of follow-up, 18 died, and 22 were lost to follow-up. The cumulative relapse rate during the first 10 years was 90% (95% confidence interval, 86%-94%), and the cumulative probability of surgery was 37.9% (95% confidence interval, 31.4%-44.4%). Terminal ileal location (P < .001), stricturing (P = .004), penetrating behavior (P < .001), and age younger than 40 years (P = .03) at diagnosis were independent risk factors for subsequent surgery. A total of 53% (n = 105) of the patients had developed stricturing or penetrating disease at 10 years. A large proportion of patients (44%) were in clinical remission during the last 5 years of follow-up.

Conclusions: The prognosis for CD seems better than previously reported. The probability of surgery was low, and fewer than expected developed complicated disease behavior. Nevertheless, the cumulative relapse rate of 90% and the finding of prognostic risk factors for subsequent surgery might call for attention to early effective medical treatment strategies.

Citing Articles

In Vitro Inhibition of Endoplasmic Reticulum Stress: A Promising Therapeutic Strategy for Patients with Crohn's Disease.

Rodrigues B, Pascoal L, Genaro L, Warrak L, Rodrigues B, Coope A Cells. 2025; 14(4).

PMID: 39996742 PMC: 11853800. DOI: 10.3390/cells14040270.


Health-care resource use and costs associated with inflammatory bowel disease in northwest London: a retrospective linked database study.

Ui-Haq Z, Causin L, Kamalati T, Kahol D, Vaikunthanathan T, Wong C BMC Gastroenterol. 2024; 24(1):480.

PMID: 39736541 PMC: 11684289. DOI: 10.1186/s12876-024-03559-3.


Progression of Crohn's Disease in Newly Diagnosed Patients: Results from an Observational Study Using US Claims Data.

Fan Y, Zhang L, Omidakhsh N, Bohn R, Putnam K, Adewale A Dig Dis Sci. 2024; 69(11):4167-4177.

PMID: 39438411 PMC: 11567996. DOI: 10.1007/s10620-024-08591-7.


Ten-year outcomes of a prospective population-based incidence cohort of inflammatory bowel disease patients from Canterbury, New Zealand.

Forbes A, Frampton C, Day A, DeVries M, McVicar N, Su H JGH Open. 2024; 8(10):e70038.

PMID: 39403112 PMC: 11472240. DOI: 10.1002/jgh3.70038.


Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration.

Patel S, Walsh J, Pinnell D, Pei S, Chen W, Rojas J Medicine (Baltimore). 2024; 103(37):e39476.

PMID: 39287304 PMC: 11404896. DOI: 10.1097/MD.0000000000039476.